Basel, Switzerland, April 20, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that a broad range of posters and presentations on the antifungal isavuconazole (Cresemba®) and the antibiotic ceftobiprole (Zevtera®) will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), which will be held in Madrid, Spain, from April 21 to 24, 2018.

Basel, Switzerland, April 18, 2017 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that shareholders approved all proposals of the Board of Directors at today's Annual General Meeting of Shareholders (AGM) for the financial year 2017.The shareholders approved the annual report, the financial statements, and consolidated financial statements for the financial year 2017, and approved the discharge of the members of Basilea's Board of Directors and Management Committee. Shareholders also approved carrying forward the accumulated deficit, and re-elected PricewaterhouseCoopers AG, Basel, as auditors.

Basel, Switzerland, April 18, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that its license partner Asahi Kasei Pharma Corporation ("Asahi Kasei Pharma") has started enrollment in a clinical phase 3 study with the antifungal isavuconazole for the treatment of deep-seated mycosis, comprised of invasive aspergillosis, chronic pulmonary aspergillosis, mucormycosis and cryptococcosis. The study is part of an abbreviated development program. If the study is successfully completed, Asahi Kasei Pharma plans to proceed with the submission of a marketing authorization application for isavuconazole in Japan.

Basel, Switzerland, April 17, 2018 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into a license agreement with ArQule, Inc. (NASDAQ: ARQL) for its oncology drug candidate ARQ 087 (derazantinib), which targets the fibroblast growth factor receptor (FGFR) family of kinases. The exclusive license is worldwide, excluding the People's Republic of China, Hong Kong, Macau and Taiwan.